Co-founded by Jennifer Doudna, Caribou develops allogeneic (off-the-shelf) cell therapies using its proprietary chRDNA CRISPR hybrid system. Their lead programs in hematological cancers use CRISPR-edited donor T cells that are engineered to avoid graft-versus-host disease, enabling scalable, off-the-shelf CAR-T products.